Opzelura (Ruxolitinib)

Ruxolitinib blocks the activity of Janus kinase 1 and 2 (JAK1/JAK2), key enzymes in the cytokine signaling cascade. By inhibiting these kinases, the drug prevents the activation of STAT proteins, which reduces the production of inflammatory mediators in the skin and thereby diminishes the symptoms of inflammatory dermatoses.

The exact amount of Opzelura to apply is determined by the prescribing clinician based on disease severity, affected body surface area, and patient age. Typically, a thin layer is spread over the affected skin once or twice daily, but the prescriber will provide specific instructions tailored to each individual.

Safety data for Opzelura in pregnancy and lactation are limited. The product should be avoided unless the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or nursing should discuss alternative options with their healthcare provider.

To request Opzelura, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

Opzelura offers a targeted, topical JAK‑inhibition approach, which differs from traditional topical steroids or calcineurin inhibitors that act more broadly on inflammation. Compared with systemic JAK inhibitors, Opzelura provides localized activity with lower systemic exposure, potentially reducing systemic side‑effects while still delivering effective control of moderate‑to‑severe disease.

Opzelura should be stored at room temperature, preferably below 25 °C, in its original container. Keep the tube tightly closed, protect it from direct sunlight, and avoid exposure to moisture. Do not freeze the product. If the cream appears discoloured or contaminated, discard it and obtain a new supply.

Before application, wash and gently pat the affected skin dry. Apply a thin, even layer of the cream to the designated area(s) and rub gently until fully absorbed. Follow the prescriber’s frequency instructions, usually once or twice daily, and wash your hands after each application unless the hands are being treated.

Serious risks include secondary skin infections, severe allergic reactions such as angioedema, systemic immunosuppression that may predispose to opportunistic infections, and a potential increased risk of malignancy with prolonged use. Patients should be monitored regularly for signs of infection, unusual skin changes, or systemic symptoms and report them promptly.

Opzelura is contraindicated in individuals with a known hypersensitivity to ruxolitinib or any component of the cream. It should also be avoided in patients with active skin infections, those receiving live attenuated vaccines, and anyone using systemic JAK inhibitors unless specifically directed by a specialist. Pregnant or breastfeeding women should only use it if clearly advised by their physician.